Lifecore Biomedical Gets Notice From Nasdaq Regarding Delayed Annual Report
Portfolio Pulse from Benzinga Newsdesk
Lifecore Biomedical has received a notice from Nasdaq regarding a delay in their annual report. The company has until October 16, 2023, to submit a plan to regain compliance with the Listing Rule.
August 22, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lifecore Biomedical has been given a notice by Nasdaq due to a delay in their annual report. They have until October 16, 2023, to submit a plan to regain compliance.
The notice from Nasdaq is a significant regulatory issue for Lifecore Biomedical. Failure to submit a plan for compliance within the given timeframe could lead to further regulatory actions, including potential delisting. This uncertainty could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100